Exelixis
EXEL
#1644
Rank
C$14.19 B
Marketcap
$51.51
Share price
0.98%
Change (1 day)
61.91%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2023 (TTM): $0.38

According to Exelixis's latest financial reports the company's current EPS (TTM) is $0.39. In 2022 the company made an earnings per share (EPS) of $0.79 a decrease over its 2021 EPS that were of $1.03.

EPS history for Exelixis from 2000 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$0.38-52.46%
2022$0.79-22.97%
2021$1.03100%
2020$0.51-65.09%
2019$1.47-53.91%
2018$3.19333.96%
2017$0.74-260.61%
2016-$0.46-58.75%
2015-$1.11-42.45%
2014-$1.935.3%
2013-$1.8343.48%
2012-$1.28-264.29%
2011$0.78-165.88%
2010-$1.18-32.54%
2009-$1.75-17.65%
2008-$2.1275.86%
2007-$1.21-25.64%
2006-$1.628.33%
2005-$1.50-42.86%
2004-$2.6230.34%
2003-$2.01-5.23%
2002-$2.12-0.65%
2001-$2.14-51.88%
2000-$4.44

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
$4.86 1,135.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
$4.41 1,022.57%๐Ÿ‡ซ๐Ÿ‡ท France
$2.53 543.02%๐Ÿ‡บ๐Ÿ‡ธ USA
$5.51 1,301.34%๐Ÿ‡บ๐Ÿ‡ธ USA
$19.63 4,894.71%๐Ÿ‡บ๐Ÿ‡ธ USA
$19.54 4,871.87%๐Ÿ‡บ๐Ÿ‡ธ USA
$2.58 556.55%๐Ÿ‡บ๐Ÿ‡ธ USA
-$13.87-3,629.83%๐Ÿ‡บ๐Ÿ‡ธ USA
-$1.17-396.51%๐Ÿ‡บ๐Ÿ‡ธ USA